|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2007-3-5
|
|
pubmed:abstractText |
Neonatal necrotizing enterocolitis (NEC) is a common and serious acquired gastrointestinal tract condition. This clinical study assessed the potential clinical efficacy and microscopic effects of recombinant human epidermal growth factor 1-48 (EGF(1-48)) in neonates with NEC.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1531-5037
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
42
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
462-9
|
|
pubmed:dateRevised |
2007-8-16
|
|
pubmed:meshHeading |
pubmed-meshheading:17336181-Double-Blind Method,
pubmed-meshheading:17336181-Enterocolitis, Necrotizing,
pubmed-meshheading:17336181-Epidermal Growth Factor,
pubmed-meshheading:17336181-Female,
pubmed-meshheading:17336181-Gastrointestinal Agents,
pubmed-meshheading:17336181-Humans,
pubmed-meshheading:17336181-Infant,
pubmed-meshheading:17336181-Infant, Newborn,
pubmed-meshheading:17336181-Intestinal Mucosa,
pubmed-meshheading:17336181-Male,
pubmed-meshheading:17336181-Peptide Fragments,
pubmed-meshheading:17336181-Prospective Studies
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Intestinal mucosa remodeling by recombinant human epidermal growth factor(1-48) in neonates with severe necrotizing enterocolitis.
|
|
pubmed:affiliation |
Department of Paediatrics, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK. peter.sullivan@paediatrics.ox.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
